Cargando…

Identification of 1,2,4-Oxadiazoles-Based Novel EGFR Inhibitors: Molecular Dynamics Simulation-Guided Identification and in vitro ADME Studies

BACKGROUND: In this work, we have identified heterocyclic derivatives with 1,2,4 oxadiazole scaffold mimicking the functions of tyrosine kinase inhibitors. Fourteen molecules that displayed the best fit were picked from the library of compounds and studied under in-silico and in-vitro conditions. Fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Unadkat, Vishal, Rohit, Shishir, Parikh, Paranjay, Patel, Kaushal, Sanna, Vinod, Singh, Sanjay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077134/
https://www.ncbi.nlm.nih.gov/pubmed/35535170
http://dx.doi.org/10.2147/OTT.S357765
_version_ 1784702071394533376
author Unadkat, Vishal
Rohit, Shishir
Parikh, Paranjay
Patel, Kaushal
Sanna, Vinod
Singh, Sanjay
author_facet Unadkat, Vishal
Rohit, Shishir
Parikh, Paranjay
Patel, Kaushal
Sanna, Vinod
Singh, Sanjay
author_sort Unadkat, Vishal
collection PubMed
description BACKGROUND: In this work, we have identified heterocyclic derivatives with 1,2,4 oxadiazole scaffold mimicking the functions of tyrosine kinase inhibitors. Fourteen molecules that displayed the best fit were picked from the library of compounds and studied under in-silico and in-vitro conditions. Four compounds were selected for further cytotoxicity and ADME (Absorption, Distribution, Metabolism, Elimination) profiling showing IC(50) (from 8–13 µM) values against EGFR positive cancer cell line (MCF7). METHODS: A molecular dynamics simulation study was performed to understand the correlation of non-covalent binding energies with biological activity. The drug-like properties of the selected four compounds (7a, 7b, 7e, and 7m) were evaluated by in-vitro ADME studies. Compounds 7a, 7b, and 7m were the active compounds in the molecular dynamics simulations study. Further, EGFR binding activity was confirmed with EGFR(WT) and EGFR(T790M) kinase assay using a luminescence-based method. RESULTS: These compounds (7a, 7b, and 7m) showed activity against EGFR(WT) and mutant EGFR(T790M), exhibiting IC(50) values of <10 and <50 micromolar, respectively. These compounds also possess moderate aqueous solubility in 40–70 µg/mL at pH 7.4 and 30–100 µg/mL at pH 4.0. Further, 7a, 7b, and 7m showed balanced lipophilicity with Log D values ranging from 1–3. They demonstrated a good correlation in Caco-2 permeability with Apparent permeability (Papp) 1 to 5 × 10(−6) cm/s in comparison with 7e, which was found to be highly lipophilic (Log D >5) and showed high permeability (Papp 17 × 10(−6) cm/s). Lastly, all these compounds were moderately stable in liver microsomes at alkaline pH with a half-life of 30–60 min, while at a highly acidic pH (2.0), the compounds were stable up to 15–20 min. CONCLUSION: Overall, in-vitro ADME results of these molecules showed good drug-like properties, which are well correlated with the in-silico ADME data, making them ideal for developing an oral drug delivery formulation.
format Online
Article
Text
id pubmed-9077134
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-90771342022-05-08 Identification of 1,2,4-Oxadiazoles-Based Novel EGFR Inhibitors: Molecular Dynamics Simulation-Guided Identification and in vitro ADME Studies Unadkat, Vishal Rohit, Shishir Parikh, Paranjay Patel, Kaushal Sanna, Vinod Singh, Sanjay Onco Targets Ther Original Research BACKGROUND: In this work, we have identified heterocyclic derivatives with 1,2,4 oxadiazole scaffold mimicking the functions of tyrosine kinase inhibitors. Fourteen molecules that displayed the best fit were picked from the library of compounds and studied under in-silico and in-vitro conditions. Four compounds were selected for further cytotoxicity and ADME (Absorption, Distribution, Metabolism, Elimination) profiling showing IC(50) (from 8–13 µM) values against EGFR positive cancer cell line (MCF7). METHODS: A molecular dynamics simulation study was performed to understand the correlation of non-covalent binding energies with biological activity. The drug-like properties of the selected four compounds (7a, 7b, 7e, and 7m) were evaluated by in-vitro ADME studies. Compounds 7a, 7b, and 7m were the active compounds in the molecular dynamics simulations study. Further, EGFR binding activity was confirmed with EGFR(WT) and EGFR(T790M) kinase assay using a luminescence-based method. RESULTS: These compounds (7a, 7b, and 7m) showed activity against EGFR(WT) and mutant EGFR(T790M), exhibiting IC(50) values of <10 and <50 micromolar, respectively. These compounds also possess moderate aqueous solubility in 40–70 µg/mL at pH 7.4 and 30–100 µg/mL at pH 4.0. Further, 7a, 7b, and 7m showed balanced lipophilicity with Log D values ranging from 1–3. They demonstrated a good correlation in Caco-2 permeability with Apparent permeability (Papp) 1 to 5 × 10(−6) cm/s in comparison with 7e, which was found to be highly lipophilic (Log D >5) and showed high permeability (Papp 17 × 10(−6) cm/s). Lastly, all these compounds were moderately stable in liver microsomes at alkaline pH with a half-life of 30–60 min, while at a highly acidic pH (2.0), the compounds were stable up to 15–20 min. CONCLUSION: Overall, in-vitro ADME results of these molecules showed good drug-like properties, which are well correlated with the in-silico ADME data, making them ideal for developing an oral drug delivery formulation. Dove 2022-05-02 /pmc/articles/PMC9077134/ /pubmed/35535170 http://dx.doi.org/10.2147/OTT.S357765 Text en © 2022 Unadkat et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Unadkat, Vishal
Rohit, Shishir
Parikh, Paranjay
Patel, Kaushal
Sanna, Vinod
Singh, Sanjay
Identification of 1,2,4-Oxadiazoles-Based Novel EGFR Inhibitors: Molecular Dynamics Simulation-Guided Identification and in vitro ADME Studies
title Identification of 1,2,4-Oxadiazoles-Based Novel EGFR Inhibitors: Molecular Dynamics Simulation-Guided Identification and in vitro ADME Studies
title_full Identification of 1,2,4-Oxadiazoles-Based Novel EGFR Inhibitors: Molecular Dynamics Simulation-Guided Identification and in vitro ADME Studies
title_fullStr Identification of 1,2,4-Oxadiazoles-Based Novel EGFR Inhibitors: Molecular Dynamics Simulation-Guided Identification and in vitro ADME Studies
title_full_unstemmed Identification of 1,2,4-Oxadiazoles-Based Novel EGFR Inhibitors: Molecular Dynamics Simulation-Guided Identification and in vitro ADME Studies
title_short Identification of 1,2,4-Oxadiazoles-Based Novel EGFR Inhibitors: Molecular Dynamics Simulation-Guided Identification and in vitro ADME Studies
title_sort identification of 1,2,4-oxadiazoles-based novel egfr inhibitors: molecular dynamics simulation-guided identification and in vitro adme studies
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077134/
https://www.ncbi.nlm.nih.gov/pubmed/35535170
http://dx.doi.org/10.2147/OTT.S357765
work_keys_str_mv AT unadkatvishal identificationof124oxadiazolesbasednovelegfrinhibitorsmoleculardynamicssimulationguidedidentificationandinvitroadmestudies
AT rohitshishir identificationof124oxadiazolesbasednovelegfrinhibitorsmoleculardynamicssimulationguidedidentificationandinvitroadmestudies
AT parikhparanjay identificationof124oxadiazolesbasednovelegfrinhibitorsmoleculardynamicssimulationguidedidentificationandinvitroadmestudies
AT patelkaushal identificationof124oxadiazolesbasednovelegfrinhibitorsmoleculardynamicssimulationguidedidentificationandinvitroadmestudies
AT sannavinod identificationof124oxadiazolesbasednovelegfrinhibitorsmoleculardynamicssimulationguidedidentificationandinvitroadmestudies
AT singhsanjay identificationof124oxadiazolesbasednovelegfrinhibitorsmoleculardynamicssimulationguidedidentificationandinvitroadmestudies